Results of a phase III randomized controlled trial of the safety and efficacy of atrasentan in men with nonmetastatic hormone-refractory prostate cancer (HRPC)

被引：0
|
作者：
Nelson, J. B.
Chin, J. L.
Love, W.
Schulman, C.
Sleep, D.
Qian, J.
Steinberg, J.
Hintzman, P.
Dawson, M.
Carducci, M.
机构：
[1] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA
[2] London Hlth Sci Ctr, London, ON, Canada
[3] Urol Res Ctr, Burlington, ON, Canada
[4] Hop Erasme, Brussels, Belgium
[5] Abbott, Abbott Pk, IL USA
[6] Johns Hopkins Univ, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5018
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer
    Carducci, Michael A.
    Saad, Fred
    Abrahamsson, Per-Anders
    Dearnaley, David R.
    Schulman, Claude C.
    North, Scott A.
    Sleep, Darryl J.
    Isaacson, Jeffrey D.
    Nelson, Joel B.
    CANCER, 2007, 110 (09) : 1959 - 1966
  • [2] Phase 3, Randomized, Controlled Trial of Atrasentan in Patients With Nonmetastatic, Hormone-Refractory Prostate Cancer
    Nelson, Joel B.
    Love, William
    Chin, Joseph L.
    Salad, Fred
    Schulman, Claude C.
    Sleep, Darryl J.
    Qian, Jiang
    Steinberg, Joyce
    Carducci, Michael
    CANCER, 2008, 113 (09) : 2478 - 2487
  • [3] A phase I/II study of docetaxel and atrasentan in men with metastatic hormone-refractory prostate cancer (HRPC)
    George, DJ
    Gockerman, JP
    Petros, W
    Haley, S
    Franklin, AD
    Creel, PA
    Turner, AG
    Sleep, D
    Hurwitz, HI
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 419S - 419S
  • [4] Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: A randomized, phase II, placebo-controlled trial
    Carducci, MA
    Padley, RJ
    Breul, J
    Vogelzang, NJ
    Zonnenberg, BA
    Daliani, DD
    Schulman, CC
    Nabulsi, AA
    Humerickhouse, RA
    Weinberg, MA
    Schmitt, JL
    Nelson, JB
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (04) : 679 - 689
  • [5] Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer
    Islam R. Younis
    Daniel J. George
    Terence J. McManus
    Herbert Hurwitz
    Patricia Creel
    Andrew J. Armstrong
    Jing Jie Yu
    Kristina Bacon
    Gerald Hobbs
    Cody J. Peer
    William P. Petros
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 991 - 997
  • [6] Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer
    Younis, Islam R.
    George, Daniel J.
    McManus, Terence J.
    Hurwitz, Herbert
    Creel, Patricia
    Armstrong, Andrew J.
    Yu, Jing Jie
    Bacon, Kristina
    Hobbs, Gerald
    Peer, Cody J.
    Petros, William P.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (05) : 991 - 997
  • [7] Predictive modelling in hormone-refractory prostate cancer (HRPC)
    Bellmunt, Joaquim
    Carles, Joan
    Albanell, Joan
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2009, 11 (02): : 82 - 85
  • [8] The efficacy of gemcitabine in controlling pain and improving performance status in men with hormone-refractory prostate cancer (HRPC)
    Ahmann, FR
    Burris, HA
    Nguyen, B
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 148 - 148
  • [9] Predictive modelling in hormone-refractory prostate cancer (HRPC)
    Joaquim Bellmunt
    Joan Carles
    Joan Albanell
    Clinical and Translational Oncology, 2009, 11 : 82 - 85
  • [10] Hormone-refractory prostate cancer (HRPC): Results of treatment with oral cyclophosphamide (CTX)
    Nogueira-Costa, R
    Duarte, RC
    Ramos, LAG
    Bretas, FFH
    Bicalho, OJ
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S349 - S350
12345